baicalin has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, S; He, L; Li, L; Liu, M; Wang, S | 1 |
| Cao, J; Hang, Y; Qin, X; Ren, T | 1 |
1 trial(s) available for baicalin and Coronary Artery Disease
| Article | Year |
|---|---|
Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Antirheumatic Agents; Apolipoproteins; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovascular Agents; Coronary Artery Disease; Cytokines; Double-Blind Method; Drug Administration Schedule; Female; Flavonoids; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Treatment Outcome; Triglycerides | 2018 |
1 other study(ies) available for baicalin and Coronary Artery Disease
| Article | Year |
|---|---|
Baicalin relieves TNF-α-evoked injury in human aortic endothelial cells by up-regulation of miR-145.
Topics: Aorta; Apoptosis; Cell Survival; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Flavonoids; Humans; Inflammation; MicroRNAs; p38 Mitogen-Activated Protein Kinases; Transcriptional Activation; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular System Injuries | 2020 |